Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism
- PMID: 8349811
- PMCID: PMC294906
- DOI: 10.1172/JCI116642
Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism
Abstract
To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (approximately 115 microU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (approximately 5,000 microU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (approximately 13 microU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.
Similar articles
-
Alterations in angiotensin II release and vascular reactivity in hypertensive men: a pilot study.Am J Hypertens. 1999 Nov;12(11 Pt 1):1055-62. doi: 10.1016/s0895-7061(99)00137-5. Am J Hypertens. 1999. PMID: 10604480 Clinical Trial.
-
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.Hypertension. 2002 Dec;40(6):872-9. doi: 10.1161/01.hyp.0000040262.48405.a8. Hypertension. 2002. PMID: 12468572
-
Training-induced enhancement of insulin action in human skeletal muscle: the influence of aging.J Gerontol A Biol Sci Med Sci. 1996 Jul;51(4):B247-52. doi: 10.1093/gerona/51a.4.b247. J Gerontol A Biol Sci Med Sci. 1996. PMID: 8680988
-
Angiotensin II induces insulin resistance independent of changes in interstitial insulin.Am J Physiol. 1999 Nov;277(5):E920-6. doi: 10.1152/ajpendo.1999.277.5.E920. Am J Physiol. 1999. PMID: 10567021
-
A dynamic model of angiotensin II infusion experiments.J Biomed Eng. 1989 Jan;11(1):63-71. doi: 10.1016/0141-5425(89)90168-4. J Biomed Eng. 1989. PMID: 2648070 Review.
Cited by
-
Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans.J Clin Invest. 1995 Aug;96(2):786-92. doi: 10.1172/JCI118124. J Clin Invest. 1995. PMID: 7635973 Free PMC article.
-
Differential predictors of insulin resistance in nondiabetic salt-resistant and salt-sensitive subjects.Hypertension. 2013 Mar;61(3):707-15. doi: 10.1161/HYPERTENSIONAHA.111.00423. Epub 2013 Jan 2. Hypertension. 2013. PMID: 23283360 Free PMC article.
-
Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography.J Clin Invest. 1996 Apr 1;97(7):1741-7. doi: 10.1172/JCI118601. J Clin Invest. 1996. PMID: 8601640 Free PMC article. Clinical Trial.
-
Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action.J Clin Invest. 1998 Oct 1;102(7):1403-12. doi: 10.1172/JCI3030. J Clin Invest. 1998. PMID: 9769333 Free PMC article.
-
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23. Clin Pharmacol Ther. 2022. PMID: 34312836 Free PMC article.